In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS)
Lymphoproliferation, chronic B cell activation resulting in hypergammaglobulinemia, and profound immunodeficiency are prominent features of a retrovirus-induced syndrome designated murine acquired immunodeficiency syndrome (MAIDS). In vivo treatment of infected mice with recombinant interleukin 12 (...
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
The Rockefeller University Press
1994
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191803/ |